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Abstract: Digital ulcers (DUs) are a severe and frequent clinical feature of patients with systemic 
sclerosis (SSc). The presence of DUs may cause severe pain and often lead to impairment of 
patient’s functional activities and health-related quality of life. Moreover, poor patient coopera-
tion during the wound care procedure due to pain may be associated with a negative outcome 
of DU healing. Therefore, pain management has a key role in patients with SSc. These two 
case reports describe the effectiveness and safety of oxycodone/naloxone in patients with SSc 
complicated by painful chronic DUs. Such a therapy has provided pain relief and consequently 
an increased compliance during redressing wounds.
Keywords: oxycodone, naloxone, systemic sclerosis, pain, digital ulcer, scleroderma, analgaesia, 
wound healing, opioids, calcinosis, UCLA-SCTC GIT 2.0
Introduction
Systemic sclerosis (SSc) is a complex multisystem disorder characterized by immune 
system activation, vascular involvement, and multiorgan fibrosis.1 Vasculopathy is 
postulated to have a key role in the early pathogenesis of SSc and in some of the 
complications of the disease, such as digital ulcerations.
Digital ulcers (DUs) are a serious and burdensome clinical manifestation of SSc, 
typically occurring on the fingertips or over the extensor aspects of the hands, and 
may also be related to calcinosis or become infected. Approximately 50% of patients 
report a previous history of DUs,2 often occurring early3 and predicting a worse dis-
ease course.4
The presence of DUs accounts for much of the pain in SSc and is significantly 
associated with disability,5 affecting the impairment of daily activities,6 reduction 
in quality of life,7 and a negative impact on occupation.8 Indeed, patients with SSc 
report the impact of DUs as worse than other disease manifestations, such as lung and 
gastrointestinal (GI) problems.9
Despite the impact of DUs, there is currently a limited evidence base to guide the 
management of DUs in patients with SSc. In addition to vasodilator therapy, wound care 
is pivotal, and sometimes surgical debridement is required (eg, underlying calcinosis), 
but such procedures may be exquisitely painful.10 As pain management has a key role 
in wound healing and standard therapy (ie, nonsteroidal anti-inflammatory drugs) is 
often inadequate or dose limited by side effects, opioids are likely to be used.
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However, effective pain management has not been 
investigated in detail in patients with SSc and the experience 
in DUs is further limited, particularly regarding opioids such 
as oxycodone.11,12 Due to the lack of best practice consensus, 
analgesic strategies are not standardized and are mainly 
guided by a physician’s experience.
Against this background, we report the experience of a 
tertiary referral center concerning the pain management of 
two patients with SSc affected by DUs with oral prolonged-
release (PR) oxycodone/naloxone (OXN-PR) combination. 
Such a drug is approved to treat severe chronic pain non 
responsive to non-opioids. Our institutional review board 
approval was obtained for publication of this paper.
Case report 1
A 71-year-old woman with a 20-year history of diffuse cuta-
neous SSc (anti-Scl70 antibodies positive) was admitted for 
multiple recurrent DUs in August 2015.
Her history was notable for SSc multiorgan involvement 
(mildly progressive interstitial lung disease previously treated 
with cyclophosphamide, then ongoing mycophenolate, and sta-
ble esophagopathy treated with daily prokinetics, proton-pump 
inhibitors, and antacids), controlled hypertension, statin-treated 
hypercholesterolemia, osteoporosis, generalized osteoarthritis, 
and an extrapyramidal syndrome in follow-up.
New DUs developed in the third fingertip of the left hand 
and in the second fingertip of the right hand with underly-
ing calcinosis. All DUs had similar aspects: round in shape 
with a diameter of 4 mm and a depth of ~2 mm, edges were 
flat with normal surrounding skin, and bases were pink. 
In addition, the patient had multiple concurrent scars from 
the second to the fourth fingertips bilaterally. During admis-
sion, swabs collected from all DUs were cultured and the 
findings were negative.
Full-dose oral calcium antagonist (nifedipine) and bosen-
tan 125 mg twice a day (bid) were regularly administered, 
and intravenous vasodilator iloprost therapy was intensified 
to daily administration and carried on as appropriate.
Despite the ongoing analgesic treatment (paracetamol 
3,000 mg daily), pain control was poor and wound care was 
limited by the intense pain. During admission, OXN-PR 
5/2.5 mg bid was started. At baseline and after 2 months 
prior to wound care, pain and GI symptoms were assessed. 
The Brief Pain Inventory was used to assess the severity of 
pain and the impact of pain on daily functions. Based on a 
verbally administered 0- to 10-point numeric rating scale,13 
the arithmetic mean of the four severity items can be used 
as measures of pain severity, while the arithmetic mean of 
the seven interference items can be used as a measure of 
pain interference (Table 1). Common adverse events of the 
GI tract related to the opioid therapy were monitored using 
the validated Italian version of UCLA Scleroderma Clinical 
Trial Consortium Gastrointestinal Tract (UCLA-SCTC GIT) 
2.0.14 UCLA-SCTC GIT 2.0 is a 7-multi-item scale with 
areas of reflux, distention/bloating, diarrhea, fecal soilage, 
constipation, emotional well-being, and social functioning. 
Each item is scored from 0 to 3 except the diarrhea and con-
stipation (range from 0–2 and 0–2.5, respectively), with the 
lower values indicating a better health-related quality of life. 
The total UCLA-SCTC GIT 2.0 score averages six of seven 
scales (excluding constipation) and is scored from 0 (no GI 
problems) to 3 (most severe).15 In this study, we used the total 
and constipation scores (Table 1).
Throughout the treatments, pain assessment showed a 
reduced numeric rating scale score in the absence of opioid-
related adverse events, particularly with regard to bowel 
movements (Table 1). The dose of OXN-PR remained 
Table 1 assessment of pain and gastrointestinal symptoms using patient-reported outcomes during treatment with oral prolonged-
release oxycodone/naloxone combination
Case report 1 Case report 2
Baseline 2 months later Baseline 2 months later
Drug and dosage
OXN-Pr daily dose (mg) 5/2.5 bid 5/2.5 bid 5/2.5 bid 5/2.5 bid
Pain assessment
Pain intensity, mean Nrs score 5/10 3/10 8/10 4/10
BPi, severity 24/50 14/50 39/50 19/50
BPi, interference 40/50 22/50 34/50 27/50
GiT symptom assessment
UCLa-sCTC GiT 2.0 total score 0.58 0.43 0.06 0.83
UCLa-sCTC GiT 2.0 constipation score 1.0 0.5 0.0 0.0
Note: Bid means twice a day.
Abbreviations: BPi, Brief Pain inventory; GiT, gastrointestinal tract; Nrs, numeric rating scale; OXN, oxycodone/naloxone; Pr, prolonged release; UCLa-sCTC GiT 2.0, 
UCLa scleroderma Clinical Trial Consortium Gastrointestinal Tract 2.0.
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stable. Residual pain was reported only during ulcer dress-
ing procedures, but compliance to wound care significantly 
ameliorated.
Case report 2
A 61-year-old woman with a 19-year history of limited cuta-
neous SSc (anticentromere antibodies positive) was admitted 
to our Rheumatology Unit for multiple recurrent infected 
DUs with underlying calcinosis.
Her history was notable for SSc-related esophagopathy 
(ongoing daily prokinetics, proton-pump inhibitors, and 
antacids), active smoking with moderate chronic obstructive 
pulmonary disease (ongoing inhaled bronchodilators), chronic 
obstructive peripheral arteriopathy (ongoing cilostazol), 
statin-treated hypercholesterolemia, and osteoporosis (ongo-
ing supplementation of calcium plus vitamin D).
Standard treatment for multiple recurrent DUs accounted 
for oral calcium antagonist (amlodipine), bosentan 125 mg 
bid, intravenous iloprost, and human immunoglobulin 
therapy every other month. For multiple calcinosis and recur-
rent DU infections, the patient underwent multiple surgical 
debridements and repeated courses of antibiotics according 
to antibiograms as appropriate.
In September 2015, DUs developed again in the fourth 
fingertip of the left hand and in the third and fifth fingertips 
of the right hand with an underlying calcinosis (Figure 1).
At the fourth fingertip of the left hand, DU was round in 
shape with a diameter of 4 mm and a depth of ~3 mm, edges 
Figure 1 Digital ulcers of the third and fifth fingertips of the right hand (A) and the fourth fingertip of the left hand (C) at baseline. The underlying calcinosis is shown in the 
plain X-ray images of the right (B) and left (D) hands.
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were flat with surrounding skin slightly inflamed, and bases 
were pink and white with an underlying calcinosis. At the third 
fingertip of the right hand, DU was round in shape with a diam-
eter of 1 mm and a depth of ~1 mm, edges were flat with normal 
surrounding skin, and base was pink. DU at the fifth fingertip 
of the right hand was round in shape with a diameter of 2 mm 
and a depth of ~3 mm, edges were flat with normal surrounding 
skin, and base was pink. In all DUs, there were no discharges 
suggesting an infection. During admission, swabs collected from 
all DUs were cultured and the findings were negative.
Iloprost administration and wound dressing procedures 
were increased (every third day). The ongoing analgesic 
treatment (paracetamol 3,000 mg daily) was insufficient for 
pain relief, hence OXN-PR 5/2.5 mg bid was started.
At baseline and after 2 months prior to wound care, the 
pain was reduced in Brief Pain Inventory domains (Table 1), 
in the absence of opioid-related adverse events and changes 
of bowel movements, according to UCLA-SCTC GIT 2.0.14 
The dose of OXN-PR remained stable. Compliance to wound 
care ameliorated as well.
Discussion
In our anecdotal experience, oral administration of a combi-
nation of opioid agonist–antagonist OXN-PR was shown to 
be effective and well tolerated in the management of chronic 
pain from DUs in SSc.
Opioids have been defined to be effective and safe in the 
treatment of chronic cancer and noncancer pain,16,17 including 
rheumatic diseases. However, reports on pain treatment in 
SSc were sporadic and limited to a few opioids, such as oral 
tramadol and oxycodone;12,18 in SSc-related DUs, the use 
of oxycodone showed efficacy with only mild side effects 
(itching, nausea, and/or dizziness), including constipation 
responsive to treatment in 51.7% of patients.12
Therefore, the experience on the use of opioids in patients 
with SSc is sparse, and concerns about GI adverse events 
should be taken into account. With particular attention to 
opioid-induced constipation in chronic noncancer pain, the 
OXN-PR combination proved to be effective and better toler-
ated when compared to oxycodone.19 Thus, OXN-PR may 
also be considered in SSc when standard nonopioid therapy 
is inadequate or limited by side effects and primarily when 
GI manifestations are a major issue. Our experience in SSc 
was consistent with previous reports in patients with non-SSc, 
and the GI tolerability of OXN-PR was excellent. Moreover, 
in both patients, pain relief was reached with the initial low 
dose (5/2.5 mg bid) without the need for a dose increase.
In addition to pain relief, pain control is fundamental 
to optimize wound care. Treatment adherence is, in effect, 
increased, and the compliance to change of wound dressings 
ameliorated as well. In our two cases, the treatment with 
oral OXN-PR allowed a better local management of DUs, 
especially in the tolerability of deep wound surgical deb-
ridement that otherwise was very difficult to carry out 
without adequate procedural pain management. Moreover, 
SSc-related calcinosis is often associated with painful DUs 
as a worsening factor.20 In both cases, calcinosis was present; 
in the past, both patients underwent calcinosis removal, but 
they did not experience any beneficial long-term effects. In 
fact, DUs improved quickly but then recurred, including 
calcinosis.
In addition to oral formulations, topical use of opi-
oids in SSc ulcers was anecdotally reported.21 In a recent 
uncontrolled trial on patients with SSc, in addition to local 
administration of anesthetics, local (and oral) morphine 
administration has been shown as a promising tool for the 
management of procedural pain in wound care of DUs in 
SSc.22 However, topical opioids are not easily accessible 
and, with regard to our experience, not available for routine 
use in clinical practice.
Conclusion
Management of pain related to DUs in SSc is a relevant, yet 
poorly investigated issue. The choice for optimal analgesia 
is often challenging, and opioids may be considered when 
standard therapy is inadequate.
In our anecdotal experience, oral administration of 
OXN-PR combination is safe and well tolerated in SSc, and it 
might be considered for DU pain and to optimize the overall 
treatment of DUs. Due to the lack of evidence base, clinical 
trials in SSc concerning opioids, especially OXN-PR, are 
warmly suggested to evaluate their effectiveness and safety 
in such populations.
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